首页> 外文期刊>Pediatric neurology >Myotoxicity of lipid-lowering agents in a teenager with MELAS mutation.
【24h】

Myotoxicity of lipid-lowering agents in a teenager with MELAS mutation.

机译:一名MELAS突变青少年的降脂药的肌毒性。

获取原文
获取原文并翻译 | 示例
       

摘要

The use of lipid-lowering statins has been associated with raised serum muscle enzymes and, occasionally, with rhabdomyolysis, especially in patients with pre-existing metabolic myopathies. The A3243G mutation is one of the most common mutations associated with mitochondrial disorders. A teenager harboring the A3243G mutation had the unusual association of hereditary glomerulopathy and recurrent episodes of raised creatine kinase levels with the use of lipid-lowering agents. Muscle biopsy showed both normal respiratory chain enzyme activities and normal coenzyme Q(10) levels, although decreased muscle coenzyme Q(10) concentration had been postulated to have a pathogenic role in statin-related myopathies. The close temporal relationship of statin administration and raised creatine kinase levels in this patient suggests caution in the use of statins in children and teenagers with mitochondrial myopathies.
机译:降脂他汀类药物的使用与血清肌酶升高有关,偶尔与横纹肌溶解有关,特别是在已有代谢性肌病的患者中。 A3243G突变是与线粒体疾病相关的最常见突变之一。一名携带A3243G突变的少年与遗传性肾小球病和使用降脂药反复发作的肌酸激酶水平反复发作之间存在异常联系。肌肉活检显示正常的呼吸链酶活性和正常的辅酶Q(10)水平,尽管已经假定降低的肌肉辅酶Q(10)浓度在他汀类药物相关的肌病中具有致病作用。他汀类药物的给药与肌酸激酶水平升高的时间关系密切,提示线粒体肌病儿童和青少年应谨慎使用他汀类药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号